| Medical and Health Sciences | 2021-2025 | 686 | DE 45 | 99.85 |
| Transplantation | Lifetime | 8 | DE 2 | 99.70 |
| Nephrology | Lifetime | 675 | DE 26 | 91.20 |
| Transplantation | 2021-2025 | 2 | DE 1 | 99.81 |
| Epidemiology | 2021-2025 | 629 | DE 21 | 94.20 |
| Surgery | 2021-2025 | 890 | DE 44 | 91.83 |
| Infectious Diseases | 2021-2025 | 484 | DE 18 | 89.72 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 16 | DE 2 | 99.78 |
| Neurological Complications and Syndromes | Lifetime | 9 | DE 1 | 99.57 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 143 | DE 7 | 99.44 |
| Renal and Vascular Pathologies | Lifetime | 105 | DE 6 | 99.11 |
| Organ Donation and Transplantation | Lifetime | 82 | DE 2 | 99.15 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 150 | DE 16 | 99.03 |
| Transplantation: Methods and Outcomes | Lifetime | 152 | DE 11 | 98.91 |
| Cytomegalovirus and herpesvirus research | Lifetime | 277 | DE 15 | 98.56 |
| Renal Diseases and Glomerulopathies | Lifetime | 238 | DE 16 | 98.67 |
| Tuberous Sclerosis Complex Research | Lifetime | 34 | DE 1 | 97.87 |
| Pregnancy and Medication Impact | Lifetime | 150 | DE 6 | 97.96 |
| Complement system in diseases | Lifetime | 201 | DE 14 | 97.81 |
| Polyomavirus and related diseases | Lifetime | 256 | DE 18 | 97.59 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 429 | DE 12 | 97.80 |
| Adenosine and Purinergic Signaling | Lifetime | 361 | DE 30 | 96.13 |
| Sphingolipid Metabolism and Signaling | Lifetime | 422 | DE 55 | 94.03 |
| Organ and Tissue Transplantation Research | Lifetime | 967 | DE 52 | 85.60 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 1 | DE 1 | 99.82 |
| Renal and Vascular Pathologies | 2021-2025 | 10 | DE 1 | 99.04 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 18 | DE 1 | 97.98 |
| Organ Donation and Transplantation | 2021-2025 | 21 | DE 1 | 98.51 |
| Transplantation: Methods and Outcomes | 2021-2025 | 63 | DE 3 | 97.99 |
| Organ Transplantation Techniques and Outcomes | 2021-2025 | 107 | DE 6 | 97.69 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 111 | DE 5 | 97.46 |
| Complement system in diseases | 2021-2025 | 159 | DE 16 | 91.22 |
| Pregnancy and Medication Impact | 2021-2025 | 365 | DE 11 | 85.18 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 556 | DE 11 | 83.83 |
| Parvovirus B19 Infection Studies | 2021-2025 | 255 | DE 9 | 77.56 |
| Adenosine and Purinergic Signaling | 2021-2025 | 411 | DE 28 | 75.49 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 947 | DE 69 | 76.98 |
| Polyomavirus and related diseases | 2021-2025 | 800 | DE 62 | 73.27 |
| Neurological Complications and Syndromes | 2021-2025 | 328 | DE 14 | 70.98 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 632 | DE 43 | 41.64 |
| Organ and Tissue Transplantation Research | 2021-2025 | 819 | DE 57 | 37.88 |
